Kalaris Therapeutics, Inc. (KLRS)

Kalaris Therapeutics, Inc. (KLRS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $56.2M; returns 1 day -6.0%, 1 week -6.5%, 1 year -61.8%.

Kalaris Therapeutics, Inc. (KLRS) is a clinical-stage ophthalmology biopharmaceutical company primarily focused on the development and commercialization of treatments for prevalent neovascular retinal diseases. The company is currently pre-revenue and its business model is centered on the successful advancement and eventual commercialization of its lead product candidate, TH103.

Groups KLRS belongs to

• Biotechnology
• Biopharmaceutical
• Ophthalmology
• Clinical Stage
• Clinical Stage Biotech
• Healthcare
• Life Sciences
• Unmet Medical Needs
• R&D

KLRS financial model: income statement, cash flow and balance sheet